Ocrelizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1264 publications

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Journal: Handbook of clinical neurology

Published: January 12, 2026

A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort.

A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: January 09, 2026

Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.

Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 31, 2025

Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab: Insights From a Multicenter Case Series.

Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab: Insights From a Multicenter Case Series.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 23, 2025

Author response to letter to the editor.

Author response to letter to the editor.

Journal: Journal of the neurological sciences

Published: December 19, 2025

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study.

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study.

Journal: medRxiv : the preprint server for health sciences

Published: December 18, 2025

Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab.

Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab.

Journal: Cureus

Published: December 17, 2025

Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".

Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".

Journal: Journal of the neurological sciences

Published: November 30, 2025

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Journal: medRxiv : the preprint server for health sciences

Published: November 26, 2025

A Challenging Uncommon Presentation of Steroid-Resistant Tumefactive Multiple Sclerosis: A Brainstem Crisis Resolved With Plasma Exchange and Ocrelizumab Maintenance.

A Challenging Uncommon Presentation of Steroid-Resistant Tumefactive Multiple Sclerosis: A Brainstem Crisis Resolved With Plasma Exchange and Ocrelizumab Maintenance.

Journal: Cureus

Published: November 25, 2025

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Journal: Neurology

Published: November 24, 2025

Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple Sclerosis.

Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple Sclerosis.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Showing 1-12 of 1,264

Last Updated: 02/24/2026